![](/images/graphics-bg.png)
Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?
Joint Authors
Saleem, Azeem
Murphy, Philip
Plisson, Christophe
Lahn, Michael
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-9, 9 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-08-18
Country of Publication
Egypt
No. of Pages
9
Main Subjects
Medicine
Information Technology and Computer Science
Abstract EN
In early drug development advanced imaging techniques can help with progressing new molecular entities (NME) to subsequent phases of drug development and thus reduce attrition.
However, several organizational, operational, and regulatory hurdles pose a significant barrier, potentially limiting the impact these techniques can have on modern drug development.
Positron emission tomography (PET) of radiolabelled NME is arguably the best example of a complex technique with a potential to deliver unique decision-making data in small cohorts of subjects.
However, to realise this potential the impediments to timely inclusion of PET into the drug development process must be overcome.
In the present paper, we discuss the value of PET imaging with radiolabelled NME during early anticancer drug development, as exemplified with one such NME.
We outline the multiple hurdles and propose options on how to streamline the organizational steps for future studies.
American Psychological Association (APA)
Saleem, Azeem& Murphy, Philip& Plisson, Christophe& Lahn, Michael. 2014. Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?. The Scientific World Journal،Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-1048986
Modern Language Association (MLA)
Saleem, Azeem…[et al.]. Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?. The Scientific World Journal No. 2014 (2014), pp.1-9.
https://search.emarefa.net/detail/BIM-1048986
American Medical Association (AMA)
Saleem, Azeem& Murphy, Philip& Plisson, Christophe& Lahn, Michael. Why Are We Failing to Implement Imaging Studies with Radiolabelled New Molecular Entities in Early Oncology Drug Development?. The Scientific World Journal. 2014. Vol. 2014, no. 2014, pp.1-9.
https://search.emarefa.net/detail/BIM-1048986
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1048986